Legend Biotech Q2 FY26 turns to net income of $33.2 million; revenue rises 51.9% to $387.5 million year over year
LEGN•Balance sheet and pipeline update
- Balance sheet strengthened with $212 million in net proceeds from a 7,700,000-ADS offering; cash, cash equivalents and time deposits totaled about $965 million.
- Interim CEO Alan Bash cited continued CARVYKTI momentum and first proof-of-concept for in vivo CAR-T LB2501, reporting 100% ORR and 83.3% CR at DL2.
Q2 FY26 results and CARVYKTI sales
- Legend Biotech posted IFRS net income of $33.2 million, swinging from a loss, on total revenue of $387.5 million.
- CARVYKTI net trade sales rose 50% year over year to about $657 million, with U.S. growth of 32% and ex-U.S. growth of 128%.
- IFRS operating income improved to $57.7 million, reversing an operating loss, as collaboration revenue climbed to $326.1 million.
